Lenire Biosciences
Research - San Diego, California, United States
Lenire Biosciences Employees
Lenire Biosciences Details
Developing the first and only targeted therapy for Fragile X Syndrome (FXS) treatment-resistant anxiety. Today there are no therapeutics approved for Fragile X Syndrome world wide and no other company world wide is pursuing the treatment of anxiety in this patient population. Anxiety is by far and away the most devastating, chronic and non-diminishing, life long symptom of Fragile X Syndrome. Traditional anti-anxiety drugs do not work very well with this patient population. We have identified two potential targets in the Fragile X Brain that we believe are directly responsible for this heightened state of uncontrollable anxiety. We have also tested two classifications of compounds in pre-clinical in vivo models that show enormous promise. These advanced clinical stage compounds have for the most part been abandoned by pharmaceutical companies pursuing other indications outside of Fragile X Syndrome. We would like to speak to relevant individuals at the following companies: Abbvie, Astellas, AstraZeneca, Boehringer Ingelheim, Merck, Incyte, Pfizer, GSK, ONO, Bristol Myers Squibb or Sanofi.
